Transaction details
According to a disclosure filed with the SEC, Shannon James Samuel, a director at Xilio Therapeutics (NASDAQ: XLO), bought 5,000 shares of the company’s common stock on March 26, 2026. The filing records the aggregate cost of the purchase as $43,949 and lists a per-share price of $8.79. A footnote in the filing specifies that the executed prices for the shares ranged between $8.6758 and $9.2499. Following the transaction, Samuel directly holds 10,000 shares of Xilio Therapeutics common stock.
Market context
The director’s acquisition was executed while XLO’s trading price was $8.23, modestly below the price Samuel paid. The company’s market capitalization is $48 million. Analyst coverage cited in the filing includes a price target of $20. The filing also references InvestingPro, which reports that Xilio has more cash on its balance sheet than debt but is rapidly burning through cash. The InvestingPro note indicates that five additional ProTips and more financial metrics are available on that platform.
Recent corporate financing and clinical updates
Xilio reported receiving $35.8 million in gross proceeds from the exercise of Series B warrants. The exercise featured full participation from investors identified in the filing as Coastlands Capital, Frazier Life Sciences, and Gilead Sciences, Inc. The warrant exercise follows a follow-on public offering the company completed in June 2025.
The company has outlined regulatory and clinical milestones for its development pipeline. Xilio plans to submit an investigational new drug application for its candidate XTX501 by mid-2026. Contingent on regulatory clearance, the firm expects a Phase 1 clinical trial for XTX501 to begin in the second half of 2026. Separately, Xilio intends to present data on its experimental therapy XTX601 at the upcoming American Association for Cancer Research Annual Meeting.
Corporate action
Shareholders approved a 1-for-14 reverse stock split of Xilio’s common stock at a special meeting. The company will implement the reverse split effective at 5:00 p.m. Eastern Time on Friday, as noted in its disclosure.
What this means in this report
The disclosure documents the director-level purchase and provides recent corporate-financing and development milestones as reported by the company. All transaction pricing ranges, ownership totals, financing amounts, investor participants, timetable targets for regulatory filings and trials, and the effective timing of the reverse split are taken from the company’s disclosures and related reporting cited in the filing.